Beyond Air

Company Overview

Snapshot

Founded in May 2011, Beyond Air operates with 51–200 employees. The company has raised a total of $69.54 million across seven funding rounds and is publicly traded on NASDAQ. In September 2025, Beyond Air announced the exercise of warrants, resulting in $3.25 million in gross proceeds.

Business overview

Beyond Air is a Health Tech & Life Sciences company focused on developing treatment solutions for respiratory diseases. The company utilizes its proprietary LungFit technology platform to generate nitric oxide (NO) on-demand from ambient air, delivering it to patients for various lung conditions. Its LungFit PH system, the first and only FDA-approved system with patented Ionizer technology, enables the delivery of unlimited, on-demand nitric oxide. Beyond Air serves markets in the United States and Canada, operating within the Medical Devices and Medical Treatment & Therapeutics sectors, targeting healthcare providers, patients, and pharmaceutical entities.

Strategic signal

In September 2025, Beyond Air announced the exercise of warrants, generating $3.25 million in gross proceeds. This event signals continued investor confidence and provides additional capital for the company, indicating a positive financial trajectory and potential for further development in its nitric oxide-based respiratory treatments.

Company Intelligence Q&A

What was a significant recent financial event for Beyond Air?

In September 2025, Beyond Air announced the exercise of warrants, which resulted in $3.25 million of gross proceeds for the company.

What strategic collaboration did Beyond Air enter into in 2023?

In September 2023, Beyond Air and Getz Healthcare entered into a strategic collaboration to commercialize the LungFit PH system in the Asia-Pacific region.

What was the outcome of Beyond Air's private placement offering in September 2024?

In September 2024, Beyond Air announced a private placement offering of 40.39 million shares at 51 cents per share.

What regulatory milestone did NeuroNOS achieve in September 2025?

In September 2025, NeuroNOS, a program under Beyond Air, was granted FDA Orphan Drug Designation for Glioblastoma, a primary malignant brain cancer.

What partnership did Beyond Air establish in October 2024 to expand access to its LungFit PH system?

In October 2024, Beyond Air partnered with Healthcare Links to expand access to its LungFit PH system through Group Purchasing Organizations and Integrated Delivery Networks.